Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for thrombocytopenia in low- or intermediate-risk MDS
ChiCTR2500100970Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in myelodysplastic syndrome (MDS) and Thrombocytopenia, sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoint: Proportion of platelet response to treatment. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
myelodysplastic syndrome (MDS)Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2500100970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100970.